GAfPA Blog

The GAfPA Patient Advocacy Blog

The Forgotten COVID-19 Vulnerability

As the COVID-19 crisis grows, policymakers may be overlooking a vulnerable population: patients living with rheumatic and musculoskeletal diseases like rheumatoid arthritis.

Regulators Stand Up for Biosimilars

Development of biosimilars has expanded patients’ treatment options by offering innovative medicine at lower costs than traditional biologics. So why are some nations slow to adopt biosimilars?

Sign up to receive updates from GAfPA